Screening Scientist
Contact information
Research groups
Charline Giroud
Screening Scientist
Charline Giroud graduated with a PhD degree in Biochemistry, Cellular and Molecular Biology, specialized in Virology, from the School of Medicine of Montpelier, France (2012). She studied the role of cAMP-dependent protein kinase (PKA) incorporated in HIV-1 particle, in early steps of the virus life cycle and showed that PKA acts as a cofactor of reverse transcription initiation.
She worked at the Department of Paediatric Infectious Diseases at the School of Medicine of Emory University of Atlanta, USA (2013) as a postdoctoral fellow. Using high throughput screening strategy combined to cell-based assay development, she discovered and characterized new HIV-1 and Ebola virus entry inhibitors for HIV-1 and Ebola virus entry. She started in the assay development and screening team in May 2017.
She worked at the Department of Paediatric Infectious Diseases at the School of Medicine of Emory University of Atlanta, USA (2013) as a postdoctoral fellow. Using high throughput screening strategy combined to cell-based assay development, she discovered and characterized new HIV-1 and Ebola virus entry inhibitors for HIV-1 and Ebola virus entry. She started in the assay development and screening team in May 2017.
Recent publications
-
Turning high-throughput structural biology into predictive inhibitor design.
Saar KL. et al, (2023), Proceedings of the National Academy of Sciences of the United States of America, 120
-
A Chemical Probe for Tudor Domain Protein Spindlin1 to Investigate Chromatin Function
Fagan V. et al, (2019), Journal of Medicinal Chemistry
-
Discovery of a Selective Inhibitor for the YEATS Domains of ENL/AF9.
Christott T. et al, (2018), SLAS Discov
-
Development of a YEATS-domain chemical probe
Moustakim M. et al, (2018), ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 256
-
Screening and Functional Profiling of Small-Molecule HIV-1 Entry and Fusion Inhibitors
GIROUD None. et al, (2017), ASSAY and Drug Development Technologies, 15, 53 - 63